| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 27/12/2024 | 18:38 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 28/11/2024 | 12:15 | Business Wire | Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 26/11/2024 | 14:07 | Business Wire | Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 05/11/2024 | 15:59 | Business Wire | Dr. Reddy’s Q2 & H1FY25 Financial Results | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 29/10/2024 | 05:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 25/10/2024 | 13:40 | Business Wire | Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 24/10/2024 | 22:44 | Edgar (US Regulatory) | Form SC 13G - Statement of Beneficial Ownership by Certain Investors | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 23/10/2024 | 18:18 | Edgar (US Regulatory) | Form F-6 - Registration of American Depository Receipt shares, not immediately effective | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 14/10/2024 | 15:47 | Business Wire | Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 08/10/2024 | 17:32 | Business Wire | Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 02/10/2024 | 17:10 | Business Wire | Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 20/08/2024 | 20:42 | Business Wire | Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 29/07/2024 | 17:55 | Business Wire | Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 29/07/2024 | 16:55 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 27/07/2024 | 15:51 | Business Wire | Dr. Reddy’s Q1FY25 Financial Results | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 26/06/2024 | 17:26 | Business Wire | Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 12/06/2024 | 23:05 | Edgar (US Regulatory) | Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 03/06/2024 | 19:05 | Business Wire | Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 28/05/2024 | 15:53 | Business Wire | Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 21/05/2024 | 16:05 | Business Wire | Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 21/05/2024 | 14:00 | GlobeNewswire Inc. | Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 07/05/2024 | 16:31 | Business Wire | Dr. Reddy’s Q4 & Full Year FY24 Financial Results | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 03/05/2024 | 14:00 | Business Wire | Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S. | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 22/03/2024 | 12:00 | GlobeNewswire Inc. | Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 19/03/2024 | 12:00 | Business Wire | Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 31/01/2024 | 15:44 | Business Wire | Dr. Reddy’s Q3 & 9M FY24 Financial Results | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 16/01/2024 | 14:58 | Dow Jones News | Indian Dr. Reddy's in Talks to Buy Haleon's Nicotinell, Sky News Reports | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 03/01/2024 | 12:00 | Business Wire | Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 14/12/2023 | 13:49 | Business Wire | Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index | NYSE:RDY | Dr Reddys Laboratories Ltd |
| 06/12/2023 | 13:55 | Dow Jones News | Coya Therapeutics Strikes Development, Commercialization Deal With Dr. Reddy's for ALS Drug | NYSE:RDY | Dr Reddys Laboratories Ltd |